10x Genomics, Inc.
TXG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.31 | -0.52 | -0.14 | 3.13 |
| FCF Yield | -0.33% | -0.99% | -3.98% | -0.75% |
| EV / EBITDA | -10.96 | -30.68 | -31.32 | -647.77 |
| Quality | ||||
| ROIC | -24.40% | -31.60% | -18.79% | -6.24% |
| Gross Margin | 67.86% | 66.15% | 76.69% | 84.89% |
| Cash Conversion Ratio | -0.04 | 0.06 | 0.20 | 0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.75% | 8.05% | 20.00% | 25.88% |
| Free Cash Flow Growth | 91.15% | 60.84% | -34.75% | 52.14% |
| Safety | ||||
| Net Debt / EBITDA | 1.95 | 1.29 | 0.97 | 20.55 |
| Interest Coverage | -48,639.75 | -8,040.27 | -352.82 | -61.10 |
| Efficiency | ||||
| Inventory Turnover | 2.36 | 2.84 | 1.47 | 1.24 |
| Cash Conversion Cycle | 183.03 | 168.78 | 255.66 | 273.38 |